Repare Therapeutics , a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camons...
NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, a...
Eisai Co., and Biogen announced that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Supplemental Biologics License Applicat...
HUTCHMED (China) announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in Ch...
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy ...
Thermo Fisher Scientific, a global leader in scientific research solutions, has introduced cutting-edge solutions aimed at enhancing research wor...
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent sign...
Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs has signed a Memorandum of Understanding (MOU) with Juli...
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo®(nivolumab) in combination with cisplatin and gemcitabine ...
TROPION-Lung01 Phase III trial had a local progressive or metastatic non-small cell lung cancer with at least one treatment history in the past ( Datopot...
The ALIGN study, focusing on atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, revealed a remarkable 36.1% redu...
YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer vaccines, today announced the completion of a Series A fina...
CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer. Establ...
First participants (male/female) dosed at 4,000mg over 20 minutes, with remaining subjects to be dosed in the near future - 4,000mg highest dosage to dat...
© 2025 Biopharma Boardroom. All Rights Reserved.
